These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27744144)

  • 1. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.
    Criscitiello C; Esposito A; Trapani D; Curigliano G
    Cancer Treat Rev; 2016 Nov; 50():205-207. PubMed ID: 27744144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.
    Melichar B; Študentova H; Kalábová H; Vitásková D; Čermáková P; Hornychová H; Ryška A
    Anticancer Res; 2014 Mar; 34(3):1115-25. PubMed ID: 24596349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
    Dieci MV; Radosevic-Robin N; Fineberg S; van den Eynden G; Ternes N; Penault-Llorca F; Pruneri G; D'Alfonso TM; Demaria S; Castaneda C; Sanchez J; Badve S; Michiels S; Bossuyt V; Rojo F; Singh B; Nielsen T; Viale G; Kim SR; Hewitt S; Wienert S; Loibl S; Rimm D; Symmans F; Denkert C; Adams S; Loi S; Salgado R;
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):16-25. PubMed ID: 29024776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.
    Yu X; Zhang Z; Wang Z; Wu P; Qiu F; Huang J
    Clin Transl Oncol; 2016 May; 18(5):497-506. PubMed ID: 26459255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
    Kotoula V; Chatzopoulos K; Lakis S; Alexopoulou Z; Timotheadou E; Zagouri F; Pentheroudakis G; Gogas H; Galani E; Efstratiou I; Zaramboukas T; Koutras A; Aravantinos G; Samantas E; Psyrri A; Kourea H; Bobos M; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    Oncotarget; 2016 Jan; 7(4):5074-87. PubMed ID: 26506242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of tumor-infiltrating lymphocytes in breast cancer: How to use the 2014 international guidelines?].
    Joyon N; Kordahi M; Blanc-Fournier C; Lacroix-Triki M
    Ann Pathol; 2017 Feb; 37(1):127-132. PubMed ID: 28159402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.
    Ravelli A; Roviello G; Cretella D; Cavazzoni A; Biondi A; Cappelletti MR; Zanotti L; Ferrero G; Ungari M; Zanconati F; Bottini A; Alfieri R; Petronini PG; Generali D
    Tumour Biol; 2017 Apr; 39(4):1010428317695023. PubMed ID: 28378631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Wimberly H; Brown JR; Schalper K; Haack H; Silver MR; Nixon C; Bossuyt V; Pusztai L; Lannin DR; Rimm DL
    Cancer Immunol Res; 2015 Apr; 3(4):326-32. PubMed ID: 25527356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting.
    Badr NM; Berditchevski F; Shaaban AM
    Pathobiology; 2020; 87(2):61-74. PubMed ID: 31715606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
    Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
    J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
    Raphael J; Nofech-Mozes S; Paramsothy T; Li N; Gandhi S
    Pathol Oncol Res; 2019 Oct; 25(4):1341-1347. PubMed ID: 29222623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.
    Ingold Heppner B; Loibl S; Denkert C
    Breast Care (Basel); 2016 Apr; 11(2):96-100. PubMed ID: 27239170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
    Luen SJ; Savas P; Fox SB; Salgado R; Loi S
    Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
    García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
    Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.